Ophthalmic home monitoring services provider Notal Vision (Manassas, VA), which focuses on early disease detection and treatment monitoring, has closed a Series D financing round co-led by Soleus Capital (Greenwich, CT) and the company’s majority shareholder Ganot Capital (Hollywood, FL). The investment supports the commercial growth of the company’s current service, the ForeseeHome AMD Monitoring Program, as well as the go-to-market strategy for its Home OCT pipeline optical coherence tomography (OCT) technology for monitoring wet age-related macular degeneration (wet AMD) and other retinal diseases.
“The secured funding allows us to expand the remote patient monitoring services our Medicare-accredited Notal Vision Diagnostic Clinic provides to patients by building referral partnerships with ophthalmologists, as well as a growing number of medically minded optometrists nationwide,” says Dr. Kester Nahen, CEO of Notal Vision. “The financing round lays the foundation for the market introduction of our Home OCT monitoring program for patients with exudative retinal diseases, which is highly anticipated by retina specialists and pharmaceutical companies aiming to better personalize and improve the outcome of existing anti-VEGF therapy and emerging treatment options.”